Entinostat (MS-275, SNDX-275): Epigenetic Modulation and Beyond in Oncology and Regeneration

Introduction: The Expanding Frontier of Epigenetic Modulation

Epigenetic regulation orchestrates gene expression without altering the underlying DNA sequence, acting as a pivotal modulator in both health and disease. Among the most compelling agents of epigenetic control are histone deacetylases (HDACs), a family of enzymes that condense chromatin and silence genes through the removal of acetyl groups from histone tails. Aberrant HDAC activity has been implicated in oncogenesis, tumor progression, and increasingly, in tissue regeneration dynamics. Entinostat (MS-275, SNDX-275)—a selective, orally available HDAC1 and HDAC3 inhibitor—has emerged as a powerful tool for dissecting these processes and for developing advanced translational strategies in both oncology and regenerative medicine.

Mechanism of Action of Entinostat (MS-275, SNDX-275): Targeted Epigenetic Intervention

Precision Inhibition of Class I HDACs

Entinostat, also referred to as MS-275 or SNDX-275, is a synthetic benzamide derivative that potently inhibits class I HDACs. It demonstrates remarkable selectivity, with IC₅₀ values of 0.368 μM for HDAC1 and 0.501 μM for HDAC3, while showing far weaker inhibition of HDAC8 (IC₅₀ = 63.4 μM). This selectivity profile enables researchers to interrogate the specific biological roles of HDAC1 and HDAC3 within the histone deacetylase signaling pathway, minimizing off-target effects commonly associated with pan-HDAC inhibitors.

Oral Bioavailability and Formulation Considerations

Entinostat’s oral bioavailability enhances its translational potential for in vivo studies and clinical trials. Despite its low solubility in water, it is highly soluble in DMSO (≥18.8 mg/mL) and moderately soluble in ethanol (≥7.4 mg/mL with ultrasonic assistance), offering flexibility in experimental workflows. Optimal solubility is achieved by warming to 37°C and employing ultrasonic shaking. Stock solutions are stable at -20°C for several months, though long-term solution storage is discouraged to preserve activity.

Biological Effects: Inhibition of Cancer Cell Proliferation and Apoptosis Induction

Antiproliferative and Pro-Apoptotic Actions

By inhibiting HDAC1 and HDAC3, Entinostat disrupts the regulatory balance of oncogenes and tumor suppressor genes, resulting in chromatin relaxation and reactivation of silenced genes. These epigenetic shifts culminate in pronounced anti-proliferative effects—demonstrated across an array of cancer cell lines, including breast, colon, lung, myeloma, ovarian, pancreatic, prostate, and leukemia models. Entinostat’s cytotoxicity is closely tied to the induction of apoptosis via increased reactive oxygen species (ROS), activation of caspase-3/7, and cell cycle arrest at the G1 phase.

Translational Impact in Retinoblastoma and Solid Tumors

Systemic administration of Entinostat has been shown to elevate acetyl-histone levels in retinal tissue, resulting in significant tumor burden reduction in murine and rat retinoblastoma models. Moreover, phase I clinical trials combining Entinostat with 13-cis retinoic acid (CRA) in patients with advanced solid tumors established both tolerability and recommended dosing for subsequent studies, underscoring its promise in solid tumor clinical trials and retinoblastoma treatment research.

Unveiling a New Dimension: Entinostat in Regenerative Biology

Lessons from Axolotl Limb Regeneration

While Entinostat’s role in oncology is well established, emerging evidence highlights its capacity to illuminate fundamental mechanisms in regenerative biology. A landmark study (Wang et al., 2019) demonstrated that HDAC1 activity is crucial for limb regeneration in axolotls. Notably, local injection or systemic administration of MS-275 (Entinostat) at the amputation site did not impede wound closure but significantly hindered blastema formation and subsequent limb regrowth. This effect was attributed to suppression of HDAC1 up-regulation in the wound epidermis, a process tightly regulated by nerve-derived signals and essential for dedifferentiation and proliferation of blastema cells. The findings underscore the importance of the histone deacetylase signaling pathway not only in cancer but also in vertebrate tissue regeneration, providing a compelling bridge between oncology and regenerative medicine.

Implications for Tumor Suppressor Gene Regulation and Tissue Engineering

The study by Wang et al. connects nerve-mediated HDAC1 expression to epigenetic modulation during regeneration, suggesting potential avenues for enhancing or redirecting tissue repair in mammalian systems. For cancer researchers, this duality raises intriguing questions: can modulation of HDAC1/3 activity be harnessed to both suppress tumor growth and promote healthy tissue regeneration? Could targeted inhibition or transient modulation of HDACs inform strategies in tissue engineering, particularly where precise control of cell fate and proliferation is desired?

Comparative Analysis: Entinostat Versus Alternative HDAC Inhibitors

Existing reviews—such as "Entinostat (MS-275): HDAC1/3 Inhibition for Advanced Cancer Research"—provide robust experimental workflows and troubleshooting for maximizing anti-tumor efficacy with HDAC inhibitors. However, they primarily focus on optimizing oncology protocols and translational applications. In contrast, this article explores not only Entinostat’s mechanistic depth in cancer cell proliferation inhibition and apoptosis induction, but also its underappreciated utility in elucidating regenerative biology, offering a more holistic perspective on HDAC modulation.

Comparative studies have shown that while pan-HDAC inhibitors can induce widespread gene expression changes (often leading to pronounced toxicity), selective agents like Entinostat afford more precise targeting, thereby reducing unwanted side effects and facilitating the study of specific HDAC isoforms. For instance, "Entinostat (MS-275): HDAC1/3 Inhibition in Cancer Research" discusses in vitro and translational oncology studies, but does not delve into regenerative or developmental applications. This work thus broadens the context, situating Entinostat at the interface of cancer research and regenerative medicine—two fields increasingly interlinked through advances in epigenetic science.

Advanced Applications: From Cancer Models to Regenerative Medicine

Epigenetic Modulation in Oncology: Current and Emerging Directions

In preclinical studies, Entinostat continues to serve as a gold standard for epigenetic modulation in oncology. Its ability to reactivate silenced tumor suppressor genes, inhibit cancer cell proliferation, and induce apoptosis has positioned it as a valuable tool in combination therapies—particularly with agents such as retinoids, checkpoint inhibitors, and DNA methyltransferase inhibitors. Ongoing solid tumor clinical trials are evaluating its efficacy across diverse cancer types, including hormone receptor-positive breast cancer and hematological malignancies.

Innovative Use in Regenerative Biology and Tissue Repair

Beyond oncology, Entinostat is now being leveraged to study the epigenetic underpinnings of tissue regeneration, wound healing, and cellular reprogramming. The axolotl model illustrates how targeted HDAC inhibition can reveal essential regulators of blastema formation, with potential translational relevance for mammalian regeneration and tissue engineering. These insights open new research avenues for using HDAC1 and HDAC3 inhibitors to finely tune gene expression during tissue repair, perhaps even informing the development of next-generation regenerative therapies.

Technical Considerations and Best Practices for Laboratory Use

Entinostat is supplied as a solid and should be stored at -20°C, shipped on blue ice to preserve stability. For in vitro applications, dissolving in DMSO or ethanol (with optional ultrasonic assistance) is recommended, with aliquots prepared to avoid repeated freeze-thaw cycles. In vivo studies require careful formulation to ensure bioavailability and minimize vehicle-related toxicity. APExBIO provides detailed technical guidance and high-purity Entinostat (A8171) for both basic and translational research needs.

Conclusion and Future Outlook

Entinostat (MS-275, SNDX-275) stands at the convergence of cancer research and regenerative biology, exemplifying the power of selective epigenetic modulators to unravel complex biological processes. As a highly selective oral HDAC1 and HDAC3 inhibitor, it not only advances our understanding of cancer cell proliferation inhibition and apoptosis induction in cancer cells, but also serves as a unique probe for dissecting the molecular logic of tissue regeneration. This dual utility sets Entinostat apart from other HDAC inhibitors, whose effects are often limited to oncology workflows. By integrating mechanistic insights from both cancer and regeneration, researchers can leverage Entinostat to push the boundaries of both fields, paving the way for innovative therapies and deeper systems-level understanding of epigenetic control.

To further explore Entinostat’s application in your research, consult the detailed product page at APExBIO. For workflow optimization and troubleshooting strategies focused on oncology, refer to "Entinostat (MS-275): Advancing Cancer Research via Epigenetic Modulation", which complements this article by emphasizing translational cancer models. Together, these resources empower scientists to harness the full potential of Entinostat in both established and emerging research domains.